Seegene INC.
Christine Seulki Kim is a Senior Manager at SEEGENE INC., leading strategic planning initiatives, overseeing R&D projects, and developing partnerships since June 2022. Previously, Christine served as a Korea Research Foundation Fellow at DGIST, focusing on adult stem cell regulation and organoid-based viral infectivity screening from October 2019 to May 2022. An extensive research background includes a postdoctoral position at the Max Planck Institute for Biology of Ageing, where metabolic regulation of hair follicle stem cells was investigated, and a graduate role at the University of North Carolina at Chapel Hill, with significant contributions to cystic fibrosis research. Christine is currently pursuing an MBA at Sungkyunkwan University, following a Ph.D. in Oral Biology from the University of North Carolina at Chapel Hill.
This person is not in any teams
Seegene INC.
1 followers
[INTRODUCING OUR COMPANY] The people of Seegene are on a purposeful mission to improve the world we live in. We aim to improve the quality of life for everyone globally by bringing molecular diagnostics to the masses. Molecular diagnostics is the most effective method to accurately diagnose ailments and is also the best way to diagnose them early which is when you can make the most difference in the recovery treatment. With industry-leading IP in molecular diagnostics reagent assays, we are dedicated to leveraging our unique technologies to increase our product portfolio, expand our market coverage, and lowering the total cost to serve our customers so that molecular diagnostics become a part of the fabric of everyone’s life and thus, improving the quality of life for everyone in the world. [OUR HISTORY AND OUR FUTURE] Since our founding in 2000, we have been steadfastly focused on molecular diagnostics. Currently, our product portfolio consists of over 250 molecular diagnostics reagent kits as well as a wide range of instruments and consumables that are sold globally. Testament to our expertise, when the pandemic started, Seegene was one of the first companies in the world to provide testing kits that were crucial in the fight against COVID. Today, we are a company with revenue of over $1 billion dollars and 65% gross margins. With 8 overseas entities, we generate a majority of our revenue outside of Korea. In keeping with our spirit of innovation and making a difference in the world, there are many exciting innovations being worked on at Seegene which will make it easier for the world to access the benefits of molecular diagnostics. We are transforming our business from a discrete reagent assay and instruments business to a platform business that will create new markets for molecular diagnostics and improve the quality of life for everyone. We hope that you will join us in our mission to make a meaningful difference in the world.